Dr. Darryl Sampey is a biopharmaceutical executive and company builder with more than 30 years of experience advancing biologics from discovery through clinical development and commercial manufacturing. Dr. Sampey co-founded BioFactura in 2004 and has guided the venture over the past 22 years from start-up through incubator stages to become a significant, fully-integrated biopharmaceutical product development and clinical manufacturing company. At BioFactura, he has raised more than $90M in non‑dilutive and strategic funding, built cGMP manufacturing capabilities, and led development of novel therapeutics, biodefense medical countermeasures, biosimilars and cell therapies targeting blockbuster markets. Dr. Sampey is an inventor of the VeriCyte™ Discovery and StableFast™ Biomanufacturing Platforms. He is a trusted advisor to emerging biotech ventures and established pharmaceutical companies seeking to accelerate development timelines, de‑risk CMC strategy, and scale biologics manufacturing.
Before BioFactura, Darryl Sampey led both process development and manufacturing teams at Human Genome Sciences, Inc. (HGS) honing his skills developing and scaling up new biologics processes and control strategies. During his tenure with HGS, Dr. Sampey played key roles in the start-up, commissioning, and validation of the company’s first cGMP manufacturing facility and associated development laboratories. Prior to his work at HGS, Dr. Sampey gained industrial experience in the commercial research laboratory designing and optimizing fermentation and product recovery processes for novel vaccines at North American Vaccine, Inc. His work in vaccine research has since progressed to internationally-approved vaccines for whooping cough in infants and meningitis in adults.
Dr. Darryl Sampey began his career in biotechnology at the University of Maryland graduating first in his class with a Bachelor of Science in Chemical Engineering, Magna Cum Laude, and, subsequently earned a Ph.D. in Bioengineering.